We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in South Indian coronary artery disease patients

    Govindaswamy Bharath

    Department of Genetics, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Search for more papers by this author

    ,
    Durairaj Pandian Vishnuprabu

    Department of Genetics, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Center for Vascular and Inflammatory Disease, University of Maryland Baltimore, School of Medicine, Baltimore, MD 21201, USA

    Search for more papers by this author

    ,
    Loganathan Preethi

    Department of Health Research Multi-Disciplinary Research Unit, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Department of Genetics, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Search for more papers by this author

    ,
    Arumugam Suriyam Nagappan

    Department of Health Research Multi-Disciplinary Research Unit, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Search for more papers by this author

    ,
    Ramia Thiagaraja Dhianeshwaran Isravanya

    Department of Pharmacology, Madras Medical College, Chennai, Tamil Nadu, 600003, India

    Search for more papers by this author

    ,
    Lakkakula VKS Bhaskar

    Department of Life Sciences, Guru Ghasidas University, Bilaspur, Chhattisgarh, 495009, India

    Search for more papers by this author

    ,
    Nagarajan Swaminathan

    Institute of Cardiology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, 600003, India

    Search for more papers by this author

    &
    Arasambattu Kannan Munirajan

    *Author for correspondence: Tel.: +91 442 454 7064;

    E-mail Address: akmunirajan@unom.ac.in

    Department of Genetics, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Department of Health Research Multi-Disciplinary Research Unit, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

    Search for more papers by this author

    Published Online:15 Aug 2022https://doi.org/10.2217/pgs-2022-0044

    Abstract

    Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods: Genotyping was performed using 5′-hydrolysis probe method (n = 412), and the study evaluated the treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642 genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction. Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin, and this may be useful in genotype-guided statin therapy for coronary artery disease patients.

    References

    • 1. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol. 96(5A), 24F–33F (2005).
      Medline CASGoogle Scholar
    • 2. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of different types of statins on lipid profile: a perspective on Asians. Int. J. Endocrinol. Metab. 15(2), e43319 (2017).
      MedlineGoogle Scholar
    • 3. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Biol. 29(3), 424–430 (2009).
      Medline CASGoogle Scholar
    • 4. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat. Rev. Cardiol. 15(12), 757–769 (2018).
      Medline CASGoogle Scholar
    • 5. Serban M-C, Colantonio LD, Manthripragada AD et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J. Am. Coll. Cardiol. 69(11), 1386–1395 (2017).
      Medline CASGoogle Scholar
    • 6. Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol. 6(5), 621–632 (2010).
      Medline CASGoogle Scholar
    • 7. Jacobsen W, Kuhn B, Soldner A et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28(11), 1369–1378 (2000).
      Medline CASGoogle Scholar
    • 8. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs 67(Suppl. 1), 3–15 (2007).
      Medline CASGoogle Scholar
    • 9. Kellick KA, Bottorff M, Toth PP. The National Lipid Association's Safety Task Force. A clinician's guide to statin drug–drug interactions. J. Clin. Lipidol. 8(Suppl. 3), S30–S46 (2014).
      MedlineGoogle Scholar
    • 10. Rodrigues AC, Perin PMS, Purim SG et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int. J. Mol. Sci. 12(9), 5815–5827 (2011).
      Medline CASGoogle Scholar
    • 11. Prado Y, Saavedra N, Zambrano T, Lagos J, Rosales A, Salazar LA. SLCO1B1 c.388A>G polymorphism is associated with HDL-C levels in response to atorvastatin in Chilean individuals. Int. J. Mol. Sci. 16(9), 20609–20619 (2015).
      Medline CASGoogle Scholar
    • 12. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86(2), 197–203 (2009).
      Medline CASGoogle Scholar
    • 13. Gao Y, Zhang L, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64(9), 877–882 (2008).
      Medline CASGoogle Scholar
    • 14. Willrich MAV, Hirata MH, Hirata RDC. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 10(6), 1017–1024 (2009).
      CASGoogle Scholar
    • 15. Kadam P, Ashavaid TF, Ponde CK, Rajani RM. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J. Clin. Pharm. Ther. 41(3), 329–333 (2016).
      Medline CASGoogle Scholar
    • 16. Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J. Clin. Lipidol. 5(2), 91–96 (2011).
      MedlineGoogle Scholar
    • 17. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487–497 (2005).
      Medline CASGoogle Scholar
    • 18. Patel J, Superko HR, Martin SS, Blumenthal RS, Christopher-Stine L. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis 240(1), 260–271 (2015).
      Medline CASGoogle Scholar
    • 19. Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 21(3), 296–307 (2021).
      Medline CASGoogle Scholar
    • 20. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin. Chem. 36(1), 15–19 (1990).
      Medline CASGoogle Scholar
    • 21. Sambrook J, Russell DW. Isolation of high-molecular-weight DNA from mammalian cells using proteinase K and phenol. CSH Protoc. 2006(1), pdb.prot4036 (2006).
      Google Scholar
    • 22. Reiter-Brennan C, Osei AD, Iftekhar Uddin SM et al. ACC/AHA lipid guidelines: personalized care to prevent cardiovascular disease. Cleve. Clin. J. Med. 87(4), 231–239 (2020).
      MedlineGoogle Scholar
    • 23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
      MedlineGoogle Scholar
    • 24. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80(4), 356–366 (2006).
      Medline CASGoogle Scholar
    • 25. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 9(8), 1005–1009 (2008).
      CASGoogle Scholar
    • 26. Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J. Am. Coll. Cardiol. 66(2), 184–192 (2015).
      MedlineGoogle Scholar
    • 27. Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm. J. 14(1), 4–10 (2010).
      MedlineGoogle Scholar
    • 28. Li JH, Joy SV, Haga SB et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J. Pers. Med. 4(2), 147–162 (2014).
      MedlineGoogle Scholar
    • 29. Ramsey LB, Johnson SG, Caudle KE et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 96(4), 423–428 (2014).
      Medline CASGoogle Scholar
    • 30. Rodrigues AC, Perin PMS, Purim SG et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int. J. Mol. Sci. 12(9), 5815–5827 (2011).
      Medline CASGoogle Scholar
    • 31. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297(5), 499–508 (2007).
      Medline CASGoogle Scholar
    • 32. Hirayama K, Ota T, Harada K et al. Impact of paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy on major adverse cardiovascular events in patients with stable angina pectoris. Clin. Ther. 39(2), 279–287 (2017).
      Medline CASGoogle Scholar
    • 33. Kimchi-Sarfaty C, Oh JM, Kim I-W et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525–528 (2007).
      Medline CASGoogle Scholar
    • 34. NIH. dbSNP – short genetic variations. https://ncbi.nlm.nih.gov/snp/rs1045642
      Google Scholar
    • 35. NIH. ClinVar – genomic variation as it relates to human health. https://www.ncbi.nlm.nih.gov/clinvar/variation/225939/?new_evidence=false
      Google Scholar
    • 36. Su J, Xu H, Yang J et al. ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis. 14, 122 (2015).
      MedlineGoogle Scholar
    • 37. Qu K-K, Zhang C-N, Dong L-X, Wang S-S, Zhang Z-D, Zhang L. Association of ABCB1 polymorphisms with lipid homeostasis and liver injury response to atorvastatin in the Chinese population. Can. J. Physiol. Pharmacol. 98(1), 15–22 (2020).
      Medline CASGoogle Scholar
    • 38. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26(11), 1601–1607 (2006).
      Medline CASGoogle Scholar